Dysregulation of innate and adaptive lymphoid immunity may have implications for symptom attribution and predict responses to targeted therapies in neuropsychiatric systemic lupus erythematosus.

A numerically greater proportion of patients in subgroup 1 (72.7 %) compared with those in subgroup 2 (26.7 %) showed anticipated benefit from spleen tyrosine kinase (SYK) inhibitors, but the difference did not reach statistical significance ( p = 0.054; Supplementary Table S36 ).

also in 111,027 other papers